NCT04911478Active, not recruiting
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Long-term Follow-up Protocol for Subjects Treated With Adicet Allogeneic Gamma Delta (γδ) CAR T Cell Investigational Products
Source: ClinicalTrials.gov · Last updated 9 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 23 May 2021
- Start date
- 14 Feb 2022
- Primary completion date
- Aug 2038
- Lead sponsor
- Adicet Therapeutics
- NCT number
- NCT04911478
What you commit to
- Study type: Observational
- Planned participants: 50
- From 14 Feb 2022 to the primary completion date, Aug 2038
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There are no specific exclusion criteria for this study
Who the study is looking for
- All patients who received any Adicet allogeneic CAR T investigational product and have either completed the core treatment protocol or have discontinued early
- All patients who are willing and able to adhere to the study visit schedule and other protocol requirements.
- Capable of giving signed informed consent which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and protocol
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baylor Scott & White Research Institute Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| MD Anderson Caner Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| Norton Cancer Institute Coordinator of this site? Confirm its status | Louisville | United States | Unknown status |
| Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Unknown status |
| Blood and Marrow Transplant Program Coordinator of this site? Confirm its status | Palo Alto | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.